Skip to main content
Premium Trial:

Request an Annual Quote

Celera Sells Animal Genomics Unit to MetaMorphix

NEW YORK, March  4 - Celera Genomics, in a move to hasten its metamorphosis as a drug developer, has sold its AgGen animal genomics and genotyping business to MetaMorphix, the companies said on Monday.

 

MetaMorphix will use the livestock databases to develop new products, according to a statement. The company also gets a subscription to Celera's Discovery System bioinformatics and annotation platform.

 

In return, Celera has acquired a minority interest in the company and will receive future royalties on new products that MetaMorphix develops by using the database.

 

The companies did not disclose financial details of the agreement.

 

MetaMorphix, based in Savage, Md., uses genomics and proteomics to improve livestock and other animals. It focuses on developing products that can accelerate animal growth and speed, and improve meat production, reduce waste, and decrease the use of antibiotics and hormones. The company is also working on products related to population control and behavior in pets.

 

In December, Celera sold the plant side of its AgGen division to Paradigm in a $2 million stock deal.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.